EHS
EHS

Major abortion pill maker hires its first lobbyists in Washington



WASHINGTON – GenBioPro, which sells the generic version of the abortion pill mifepristone, hired its own team of lobbyists for the first time this summer, according to new federal disclosures.

GenBioPro has hired two lobbyists from the firm Emergent Strategies to advocate on “Issues related to medication abortion … abortion access [and] FDA Approval of Mifepristone,” its filing states. Emergent officially registered to represent GenBioPro on July 11.

GenBioPro is one of just two companies in the United States that makes these pills, which terminate a pregnancy by blocking the pregnancy hormone progesterone.

advertisement

The decision to hire lobbyists is hardly surprising, given the outsized role GenBioPro is set to play in the fight over access to abortion pills in the wake of the Supreme Court’s recent decision to overturn Roe v. Wade.

In fact, GenBioPro is already at the center of a legal battle over one state’s recent efforts to ban the pill, which is FDA-approved. It sued Mississippi for restricting access to its pills, and the company is expected to file additional lawsuits in other states.

advertisement

Little is known, however, about GenBioPro and its leadership. Mifepristone is the company’s only FDA-approved product, and the company does not disclose any of its leadership online. Even the FDA keeps this information secret, for fear of violence from anti-abortion activists.

Emergent Strategies is also not well-known in the pharmaceutical industry. The firm represents only three other clients in the health care space, none of which makes drugs, according to STAT’s review. Those clients are the device lobby known as AdvaMed; the Federation of American Hospitals; and the American Health Care Association, which represents nursing homes. It’s not clear how much GenBioPro is paying Emergent for its services.

The other manufacturer of mifepristone in the United States, Danco Labs, does not currently employ any lobbyists.





Source link

EHS
Back to top button